If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
372
results.
Updated on
24/10/2026 [08:50:00]
Results 150 to 175 of 372
Absstract of: US20260284227A1
The present invention provides a method for providing modified mRNAs of reduced immunogenicity and/or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy.
Absstract of: US20260285954A1
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.
Absstract of: US20260286363A1
0000 The present disclosure provides compositions and methods of identifying, making, and using the same for the prevention and treatment of lysosomal storage diseases. Provided are also compositions and methods of diagnosing lysosomal storage diseases.
Absstract of: US20260287600A1
0000 Methods, reagents, kits and systems for analyzing different proteoforms of proteins of interest are provided. The provided methods, systems, etc. provide detection, characterization and quantitation of proteoforms for different biologically relevant proteins for monitoring and characterizing biological processes.
Absstract of: US20260285956A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Absstract of: US20260287598A1
0000 A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.
Absstract of: US20260287599A1
Embodiments of the present disclosure pertain to methods of assessing pain in a subject by receiving one or more measured levels of glycine receptors of the subject; and correlating differentially expressed levels of the glycine receptors to pain. The methods of the present disclosure may also include a step of implementing a treatment decision based on the assessment. In some embodiments, the methods of the present disclosure may be repeated after implementing the treatment decision. Additional embodiments of the present disclosure pertain to systems for assessing pain in a subject. In some embodiments, the systems include computer-readable storage mediums with program codes that implement the methods of the present disclosure.
Absstract of: AU2025226208A1
The present invention relates to an antigen combination comprising Treponema pallidum (Tp) antigens. The present invention also relates to vectors, polynucleotides, host cells and methods for producing such antigen combinations. The present invention also relates to method and uses of such antigen combinations. The present invention also relates to compositions, assays and kits and the methods and uses thereof.
Absstract of: WO2026198565A1
A method and related system for immunodiagnostic assessment of an antigen in a sample. A sample is mixed in a sample tube (i.e., cartridge) with magnetic beads and first visualization reagent which are both conjugated with antibodies for the antigen and, if the sample includes the antigen, forms magnetic immunocomplexes. The sample tube is attached to a base having a visualization chamber, the sample is flowed into the base from the sample tube, and the magnetic beads and, if formed, the magnetic immunocomplexes are advanced into the visualization window. A second visualization reagent adapted to react with the first visualization reagent to produce a visible change is introduced. An image is acquired of the visualization window with a smartphone to assess whether the visible change has occurred. The image of the visualization window acquired using the smartphone is evaluated to assess whether the antigen is present in the sample.
Absstract of: WO2026193586A1
Disclosed herein are methods of detecting at least two biomarkers in a DNA sample from a subject, the method comprising simultaneously, in a single test, amplifying the regions of DNA containing each of the at least two types of biomarkers in the DNA sample to produce amplified DNA; sequencing, by a sequencer, the amplified DNA to produce a sequencing read; and wherein the sequencing read identifies a presence and/or an absence of the at least two types of biomarkers, optionally, outputting a report indicating the presence or absence of the at least two types biomarkers in the DNA sample wherein the at least two types of biomarkers are selected from: (i) single nucleotide variations (SNVs), and/or insertion or deletion (indel) mutations; (ii) chromosomal copy number variations (CNVs), and (iii) gene CNVs.
Absstract of: WO2026198475A1
The present invention relates to an antigen-binding molecule specifically binding to methylpseudouridine or 1-methyluracil, a polynucleotide encoding it, a conjugate comprising it, and a method for producing such an antigen-binding molecule. The invention further relates to a method for detecting methylpseudouridine or 1-methyluracil, a method for detecting and/or quantifying a level of methylpseudouridine and/or 1-methyluracil, a kit for detecting presence and/or for quantifying a level of methylpseudouridine and/or 1-methyluracil, and a kit for enriching or purifying methylpseudouridine or polynucleotides containing methylpseudouridine.
Absstract of: US20260287589A1
0000 Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.
Absstract of: US20260287580A1
0000 The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from disease such as a neurological condition or disease. In general, detection or measurement of one or more biomarkers, such as neurofilament light chain (NfL), and combinations thereof with assays of the present disclosure, assists in the identification of disease such as neurological disease. The present disclosure also provides methods for selecting patients for treatment of neurological disease.
Absstract of: WO2026196014A1
The invention relates to a method for refined stage classification of a hereditary, preferably monogenic, neurodegenerative diseases mediated by an impairment of a disease-mediating gene, in disease-affected subjects. The invention also relates to diagnosis of a patient with the neurodegenerative diseases comprising classifying said patient in a stage of said disease. The subgroups react differently to treatment. In summary, the present inventors used a preclinical induced neuronal model to predict drug effectiveness in clinical trials, and have found a new dimension on prescreening patients before entering in clinical trials, thereby reducing the trial's failure.
Absstract of: US20260287581A1
0000 The present disclosure relates to a method for estimating the amount of a tau protein accumulated in the brain. One of a capture antibody and a detection antibody which are used in the method is an antibody which recognizes an amino acid sequence in a middle part of a phosphorylated tau protein, and the other is an antibody which recognizes a phosphorylated epitope including a phosphorylated amino acid residue of the phosphorylated tau protein.
Absstract of: US20260287585A1
Detecting a binding event of specific binding pair-forming substances, comprising includes: providing a layer of a first specific binding pair-forming substance (SBPS) on a substrate, providing an enclosure of the layer with a first dielectric medium (DM) rinsing the enclosure for a first time period with a second DM, restoring the first DM in the enclosure following the rinsing, feeding a solution of a second SBPS to the enclosure to cause an interaction between the first second SBPS following the restoring, incubating the enclosure for a second time period, the interaction including a binding event when the first and second SBPS provide a specific binding pair, detecting a shift in a parameter representative of a layer dielectric function following the incubating, comparing the shift with a threshold, whereby when the shift exceeds the threshold the binding event has occurred.
Absstract of: CN122790086A
0001 本发明公开了一种检测tau蛋白的抗体及其应用，涉及抗体领域。本发明公开的检测tau蛋白的抗体包括重链互补决定区和轻链互补决定区，该抗体为tau蛋白的检测提供了重要的原料来源，基于该抗体的检测，灵敏度高、特异性强，有助于阿尔茨海默病等相关疾病的预测、诊断、动态监测及预后评估，具有非常高的临床应用价值。
Absstract of: CN122794000A
本发明属于生物技术领域，具体涉及一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用。本发明一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用，诊断产品是以所述多肽或其特异性结合分子为靶分子的检测试剂盒、抗体芯片、抗体探针或检测仪。本发明克服了现有CSF‑TRUST敏感性低、常规指标特异性差的技术问题，且这种多肽标志物能够准确区分神经梅毒患者与非神经梅毒。
Absstract of: CN122790090A
0001 本发明涉及生物技术领域，具体涉及抗BD‑Tau蛋白单克隆抗体或其抗原结合片段及其应用。本发明提供的抗体对BD‑Tau蛋白具有高亲和力，能够特异性识别和结合BD‑Tau蛋白，可用于制备BD‑Tau检测试剂或试剂盒，在阿尔茨海默病的早期筛查和诊断中具有重要的应用价值。
Absstract of: US2019227064A1
0001 The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Absstract of: AU2025211997A1
Provided are an anti-albumin antibody or an antigen-binding fragment thereof and the use thereof, and an anti-albumin nanobody with improved affinity or an antigen-binding fragment thereof. The anti-albumin antibodies or antigen-binding fragments thereof can bind to albumins from different species with high affinity. In addition, the anti-albumin antibody can be linked to a bioactive effector molecule to form a fusion construct without affecting the activity of the bioactive effector molecule.
Absstract of: WO2025176707A1
The present invention relates to an agent that increases Nato3 expression and/or activity for use in preventing or treating a neurological disorder and related methods and uses. The present invention also relates to an expression construct or viral vector encoding an agent that increases Nato3 expression and/or activity and a host cell comprising said vector. The present invention also relates to a dopaminergic neuron or a dopaminergic progenitor comprising an expression construct encoding an agent that increases Nato3 expression and/or activity and a method of screening for a compound that improves dopaminergic function in a dopaminergic neuron.
Absstract of: AU2024398768A1
Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.
Absstract of: CN122772976A
0001 本发明涉及生物医药技术领域，尤其是涉及基于PRDX4的PASC相关心血管系统症状风险评估应用。本发明提供了一种以PRDX4为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Nº publicación: CN122772974A 18/09/2026
Applicant:
中日友好医院（中日友好临床医学研究所）
Absstract of: CN122772974A
本发明涉及生物医药技术领域，尤其是涉及基于SERPING1的PASC相关心血管系统症状风险评估应用。本发明提供了一种以SERPING1为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
BOPI
Electronic site
